{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:57:34Z","timestamp":1790848654188,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institutes for Drug Control Research Fund for Young and Middle-aged Development","award":["2024B2"],"award-info":[{"award-number":["2024B2"]}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z251100004625003"],"award-info":[{"award-number":["Z251100004625003"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sequence variants (SVs), unintended amino acid substitutions, represent a quality attribute of antibody therapeutics with potential safety and efficacy implications. Although control strategies are evolving, a comprehensive landscape of SVs in commercial antibody products, including biosimilars, innovators, and those from different expression systems or geographical origins, remains largely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically analyzed SVs in 51 commercial antibody therapeutics via optimized high-sensitivity LC\u2013MS\/MS peptide mapping. The panel encompassed originators and biosimilars from Chinese and multinational firms, eukaryotic (CHO, NS0) and prokaryotic (Escherichia coli) expression systems, and diverse formats (mAbs, bispecifics, ADCs) and subclasses (IgG1, IgG2, IgG4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across all products, 3006 SV occurrences were identified. The vast majority (92.5%) were\u00a0\u22640.1% per site. Only 7.5% (226 SV occurrences) exceeded 0.1%, 2.4% (72 SV occurrences) exceeded 0.2%, and a minimal 0.4% (12 SV occurrences) exceeded 0.5%. SV levels of Chinese biosimilars and innovators were comparable to international counterparts. While prokaryotic-derived products showed more SVs above 0.2%, SV levels showed no significant correlation with antibody subclasses or formats. Batch-to-batch consistency was excellent across all products.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides the largest empirical SV dataset for marketed antibody therapeutics to date. It demonstrates manufacturing processes maintain SV levels below 0.2% per site and reveals no inherent SV disparity across product origin, subclass, or format. Empirically, this 0.2% threshold serves as a pragmatic benchmark for commercial antibody quality control. These findings provide a science-based reference for establishing cell line screening in-process limits, refining industrial SV control strategies, and guiding regulatory science.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/abt\/tbag048","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:22:31Z","timestamp":1788780151000},"page":"595-605","source":"Crossref","is-referenced-by-count":0,"title":["A landscape of sequence variants in 51 commercial antibody therapeutics"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4048-6427","authenticated-orcid":false,"given":"Gangling","family":"Xu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Drug Control , Beijing, 102629 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Drug Control , Beijing, 102629 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunbo","family":"Cui","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Drug Control , Beijing, 102629 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihan","family":"Wei","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug Quality Control and Pharmacovigilance (Ministry of Education), State Key Laboratory of Natural Medicine, China Pharmaceutical University , Nanjing, 210009 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoqing","family":"Duan","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Drug Control , Beijing, 102629 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfei","family":"Cui","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Drug Control , Beijing, 102629 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu ting","family":"Mei","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Drug Control , Beijing, 102629 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanfei","family":"Yu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Drug Control , Beijing, 102629 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Drug Control , Beijing, 102629 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2026100105271003800_ref1","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41577-025-01207-9","article-title":"Fifty years of monoclonals: the past, present and future of antibody therapeutics","volume":"25","author":"Chan","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"2026100105271003800_ref2","doi-asserted-by":"publisher","first-page":"7782","DOI":"10.1021\/acs.chemrev.2c00915","article-title":"The Dawn of a new era: targeting the \u201cUndruggables\u201d with antibody-based therapeutics","volume":"123","author":"Qian","year":"2023","journal-title":"Chem Rev"},{"key":"2026100105271003800_ref3","doi-asserted-by":"publisher","first-page":"1352098","DOI":"10.3389\/fbioe.2024.1352098","article-title":"Improving product quality and productivity of an antibody-based biotherapeutic using inverted frustoconical shaking bioreactors. Front Bioeng","volume":"12","author":"Wang","year":"2024","journal-title":"Biotechnol"},{"key":"2026100105271003800_ref4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/19420862.2016.1172150","article-title":"Characterization of alanine to valine sequence variants in the fc region of nivolumab biosimilar produced in Chinese hamster ovary cells","volume":"8","author":"Li","year":"2016","journal-title":"mAbs"},{"key":"2026100105271003800_ref5","doi-asserted-by":"publisher","first-page":"115018","DOI":"10.1016\/j.jpba.2022.115018","article-title":"Mass spectrometry-based multi-attribute method for mutation analysis in the early development of therapeutic proteins","volume":"220","author":"Liu","year":"2022","journal-title":"J Pharm Biomed Anal"},{"key":"2026100105271003800_ref6","doi-asserted-by":"publisher","first-page":"1791399","DOI":"10.1080\/19420862.2020.1791399","article-title":"A general evidence-based sequence variant control limit for recombinant therapeutic protein development","volume":"12","author":"Zhang","year":"2020","journal-title":"mAbs"},{"key":"2026100105271003800_ref7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/antib11040073","article-title":"Risk-based control strategies of recombinant monoclonal antibody charge variants","volume":"11","author":"Beck","year":"2022","journal-title":"Antibodies (Basel)"},{"key":"2026100105271003800_ref8","doi-asserted-by":"publisher","first-page":"13233","DOI":"10.1038\/s41598-021-92338-1","article-title":"Identification, characterization and control of a sequence variant in monoclonal antibody drug product: a case study","volume":"11","author":"Thakur","year":"2021","journal-title":"Sci Rep"},{"key":"2026100105271003800_ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19420862.2018.1531965","article-title":"Evolution of a comprehensive, orthogonal approach to sequence variant analysis for biotherapeutics","volume":"11","author":"Lin","year":"2019","journal-title":"mAbs"},{"key":"2026100105271003800_ref10","doi-asserted-by":"publisher","first-page":"127568","DOI":"10.1016\/j.snb.2019.127568","article-title":"How to convincingly measure low concentration samples with optical label-free biosensors","volume":"306","author":"Yang","year":"2020","journal-title":"Sens Actuators B"},{"key":"2026100105271003800_ref11","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1021\/jasms.5c00085","article-title":"Feasibility of rapid regulatory differentiation of TNF receptor 2-fc fusion protein products from various manufacturers in the Chinese market using a novel mass spectrometry-based multi-attribute method (MAM)","volume":"36","author":"Xu","year":"2025","journal-title":"J Am Soc Mass Spectrom"},{"key":"2026100105271003800_ref12","doi-asserted-by":"publisher","first-page":"826923","DOI":"10.3389\/fchem.2022.826923","article-title":"Identification, efficacy, and stability evaluation of succinimide modification with a high abundance in the framework region of golimumab","volume":"10","author":"Liu","year":"2022","journal-title":"Front Chem"},{"key":"2026100105271003800_ref13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/bit.24759","article-title":"Eliminating tyrosine sequence variants in CHO cell lines producing recombinant monoclonal antibodies","volume":"110","author":"Feeney","year":"2013","journal-title":"Biotechnol Bioeng"},{"key":"2026100105271003800_ref14","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.1007\/s00253-019-09921-w","article-title":"Insight into the roles of tyrosine on rCHO cell performance in fed-batch cultures","volume":"103","author":"Tang","year":"2019","journal-title":"Appl Microbiol Biotechnol"},{"key":"2026100105271003800_ref15","doi-asserted-by":"publisher","first-page":"18584","DOI":"10.1073\/pnas.1309843110","article-title":"Large-scale detection of in vivo transcription errors","volume":"110","author":"Gout","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026100105271003800_ref16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2110797118","article-title":"Bacterial translation machinery for deliberate mistranslation of the genetic code","volume":"118","author":"Vargas-Rodriguez","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026100105271003800_ref17","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/19420862.2016.1197443","article-title":"Acid-induced aggregation propensity of nivolumab is dependent on the fc","volume":"8","author":"Liu","year":"2016","journal-title":"mAbs"},{"key":"2026100105271003800_ref18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/d41573-025-00185-w","article-title":"Innovative antibody therapeutic development in China compared with the USA and Europe","volume":"25","author":"Crescioli","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"2026100105271003800_ref19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41587-025-02998-x","article-title":"China's innovation in translational medicine: rethinking early-stage clinical development","volume":"44","author":"Tan","year":"2026","journal-title":"Nat Biotechnol"},{"key":"2026100105271003800_ref20","doi-asserted-by":"publisher","first-page":"101744","DOI":"10.1016\/j.biologicals.2024.101744","article-title":"The current status of the biosimilars landscape in China","volume":"85","author":"Xu","year":"2024","journal-title":"Biologicals"},{"key":"2026100105271003800_ref21","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1016\/s1470-2045(22)00483-1","article-title":"Accelerating the integration of China into the global development of innovative anticancer drugs","volume":"23","author":"Huang","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026100105271003800_ref22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/abt\/tbad017","article-title":"Comparability strategy and demonstration for post-approval production cell line change of a bevacizumab biosimilar IBI305","volume":"6","author":"Wu","year":"2023","journal-title":"Antib Ther"},{"key":"2026100105271003800_ref23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3390\/pathogens12030383","article-title":"Translational Fidelity during bacterial stresses and host interactions","volume":"12","author":"Lyu","year":"2023","journal-title":"Pathogens"},{"key":"2026100105271003800_ref24","doi-asserted-by":"publisher","first-page":"17117","DOI":"10.1038\/nmicrobiol.2017.117","article-title":"Translational fidelity and mistranslation in the cellular response to stress","volume":"2","author":"Mohler","year":"2017","journal-title":"Nat Microbiol"},{"key":"2026100105271003800_ref25","doi-asserted-by":"publisher","first-page":"112161","DOI":"10.1016\/j.yexcr.2020.112161","article-title":"Translational quality control and reprogramming during stress adaptation","volume":"394","author":"Han","year":"2020","journal-title":"Exp Cell Res"},{"key":"2026100105271003800_ref26","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.15159\/AR.21.083","article-title":"Improving single cell protein yields and amino acid profile via mutagenesis: review of applicable amino acid inhibitors for mutant selection","volume":"19","author":"SR","year":"2021","journal-title":"Agron Res"},{"key":"2026100105271003800_ref27","first-page":"63","volume-title":"State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2 Biopharmaceutical Characterization: The NISTmAb Case","author":"Borisov","year":"2015"},{"key":"2026100105271003800_ref28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41573-024-01051-x","article-title":"Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics","volume":"23","author":"Carter","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026100105271003800_ref29","doi-asserted-by":"publisher","first-page":"2333729","DOI":"10.1080\/19420862.2024.2333729","article-title":"In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies","volume":"16","author":"Mattei","year":"2024","journal-title":"mAbs"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbag048\/70990223\/tbag048.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/4\/595\/70990223\/tbag048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/4\/595\/70990223\/tbag048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:27:29Z","timestamp":1790846849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/9\/4\/595\/8787843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbag048","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,8]]}}}